Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 3/20 | 0.62 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.62 |
| ▸ | METAP2 | P50579 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23278791 | 0.84 | HSD17B1 (0.46) | HSD17B1HSD17B2METAP2APPHPGDS | |
| SCHEMBL17776911 | 0.81 | CYP3A4 (0.54) | HSD17B1HSD17B2METAP2APPCHRNB4 | |
| SCHEMBL28566243 | 0.81 | METAP2 (0.49) | HSD17B1HSD17B2METAP2APPMAP4K4 | |
| SCHEMBL12957239 | 0.80 | HSD17B1 (0.67) | HSD17B1HSD17B2MAP4K4HPGDSIRAK4 | |
| SCHEMBL13910991 | 0.78 | HSD17B1 (0.63) | HSD17B1HSD17B2HPGDSCYP11B1CYP11B2 | |
| SCHEMBL1181050 | 0.77 | HSD17B1 (1.00) | HSD17B1HSD17B2METAP2KDM1A | |
| SCHEMBL22652789 | 0.76 | HSD17B1 (0.48) | HSD17B1HSD17B2METAP2APPCHRNB4 | |
| SCHEMBL6561405 | 0.76 | METAP2 (0.50) | HSD17B1HSD17B2METAP2APPCHRNB4 | |
| SCHEMBL27354843 | 0.76 | CYP2A6 (0.47) | METAP2 | |
| SCHEMBL4402515 | 0.76 | HSD17B1 (0.61) | HSD17B1HSD17B2METAP2MAP4K4KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9078330-B2 | Highly branched dendrimers | ISIS INNOVATION LIMITED (GB) | 2015-07-07 | — | — | US | disclosed |
| US-20080211391-A1 | Highly Branched Dendrimers | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2008-09-04 | — | — | US | disclosed |
| WO-2006097717-A1 | HIGHLY BRANCHED DENDRIMERS | ISIS INNOVATION LIMITED (GB) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080211391-A1 | Highly Branched Dendrimers | ITGB1, PICALM, BTN3A1 | HSD17B1 829/4885HSD17B2 1602/4885METAP2 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.